Metformin Therapy in Type 2 Diabetes Management
Summary
Metformin remains the cornerstone of pharmacological intervention in type 2 diabetes mellitus, recommended universally as first-line therapy due to its efficacy, safety profile and cost-effectiveness. Its primary mode of action is suppression of hepatic gluconeogenesis, complemented by enhanced peripheral glucose uptake and modulation of the gut microbiota. Clinically, metformin lowers glycated haemoglobin (HbA1c) by approximately 1–1.5% and is associated with weight neutrality or modest weight loss. Beyond glycaemic control, emerging evidence supports cardiovascular and renal benefits, including reduced risk of atherosclerotic events and slowing of diabetic nephropathy progression. The drug exhibits a well-characterised adverse-event profile, most notably gastrointestinal intolerance, which may be mitigated by dose titration, extended-release formulations or adjunctive probiotics. In contemporary practice, metformin is often combined with second-line agents—such as DPP-4 and SGLT-2 inhibitors or GLP-1 receptor agonists—to achieve tighter glycaemic targets while minimising hypoglycaemia and weight gain. Its global relevance is underscored by use in diverse populations, with real-world data confirming consistent efficacy across ethnic groups and body-mass indices. Ongoing research addresses optimised dosing regimens, formulation improvements and potential pleiotropic actions in ageing and cancer prevention.
Research from Nature Portfolio
No recent Nature Portfolio content available.
Metformin Therapy in Type 2 Diabetes Management publication trend
The graph below shows the total number of articles in metformin therapy in type 2 diabetes management across all publications each year (not limited to Nature Index journals).
Technical terms
Gluconeogenesis: Metabolic pathway by which the liver produces glucose from non-carbohydrate substrates.
HbA1c: Glycated haemoglobin, reflecting average blood glucose over the preceding two to three months.
Extended-release formulation: A drug design that delivers active ingredient gradually to reduce dosing frequency and improve tolerability.
Gastrointestinal adverse events: Side effects affecting the digestive tract, such as nausea, diarrhoea and abdominal discomfort.
References
- Metformin-Associated Gastrointestinal Adverse Events Are Reduced by Probiotics: A Meta-Analysis. Pharmaceuticals (2024).
- Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: A systematic review, meta-analysis and meta-regression of randomized controlled trials. Frontiers in Endocrinology (2022).
- Long-Acting Metformin Vs. Metformin Immediate Release in Patients With Type 2 Diabetes: A Systematic Review. Frontiers in Pharmacology (2021).
About these summaries
This Nature Research Intelligence Topic summary is created with the cited references and a large language model. We take care to ground generated text with facts, and have systems in place to gain human feedback on the overall quality of the process in line with our AI principles. We strive to create accurate and useful summaries for people unfamiliar with the research topic and that supports this goal. These pages are a beta release and will be updated as we learn how best to help people gain value from a research topic summary.
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.